fezolinetant

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hepatic Impairment

Conditions

Hepatic Impairment, Healthy Volunteers

Trial Timeline

Sep 2, 2020 → Mar 22, 2021

NCT ID

NCT04482270

About fezolinetant

fezolinetant is a phase 1 stage product being developed by Astellas Pharma for Hepatic Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT04482270. Target conditions include Hepatic Impairment, Healthy Volunteers.

What happened to similar drugs?

3 of 18 similar drugs in Hepatic Impairment were approved

Approved (3) Terminated (5) Active (12)

✅RifaximinBausch HealthApproved

✅Placebo + RifaximinBausch HealthApproved

✅Rifaximin + LactuloseBausch HealthApproved

🔄cisplatin + gemcitabine hydrochlorideEli LillyPhase 3

🔄PhosphatidylcholineSanofiPhase 3

❌oxaliplatin (SR96669) + capecitabine + sorafenibSanofiPhase 3

🔄Givosiran + PlaceboAlnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07455812	Pre-clinical	Active	Oct 29, 2024	Jul 31, 2026	Hot Flashes
NCT04793204	Phase 1	Completed	Mar 24, 2021	May 21, 2021	Healthy Volunteers
NCT04641260	Phase 1	Completed	Nov 20, 2020	Feb 21, 2021	Healthy Subjects
NCT04482270	Phase 1	Completed	Sep 2, 2020	Mar 22, 2021	Hepatic Impairment
NCT04476849	Phase 1	Completed	Aug 10, 2020	Mar 11, 2022	Healthy Volunteers
NCT04451226	Phase 3	Completed	Jul 30, 2020	Jun 13, 2022	Hot Flashes

Competing Products

20 competing products in Hepatic Impairment

See all competitors

Product	Company	Stage	Hype Score
ITF2357	Biotrial	Phase 1	19
GB1211 + Placebo	Comac Medical	Phase 1/2	18
ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)	Idorsia	Phase 1	23
Olomorasib	Eli Lilly	Phase 1	29
Simufilam	Cassava Sciences	Phase 1	19
cisplatin + gemcitabine hydrochloride	Eli Lilly	Phase 3	40
exatecan mesylate	Daiichi Sankyo	Phase 2	35
DS-3201b	Daiichi Sankyo	Phase 1	29
Quizartinib	Daiichi Sankyo	Phase 1	29
Quizartinib	Daiichi Sankyo	Phase 1	36
Pexidartinib	Daiichi Sankyo	Phase 1	29
Tivantinib + Tivantinib + Tivantinib + Tivantinib	Daiichi Sankyo	Phase 1	29
Bocidelpar	Astellas Pharma	Phase 1	29
enzalutamide	Astellas Pharma	Phase 1	29
ASP015K	Astellas Pharma	Phase 1	29
ASP2215	Astellas Pharma	Phase 1	29
BPN14770	Shionogi	Phase 1	29
S-217622	Shionogi	Phase 1	29
Lemborexant	Eisai	Phase 1	29
Lenvatinib	Eisai	Phase 1	29